BioPharmSignal logoBioPharmSignal

Biotech News

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

Inflarx NV (IFRX)Inflarx NVCommercial

InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today is presenting its clinical development strategy and commercial vision for izicopan at the Company’s Capital Markets Day.

Related news

IFRXInflarx NV2026-10-22 16:00 EST

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

IFRXInflarx NV2026-09-21 11:30 EST

InflaRx to Host Virtual Capital Markets Day

SNYSanofi2026-10-12 16:05 EST

Sanofi: Information concerning the total number of voting rights and shares – September 2026

XFORX4 Pharmaceuticals2026-10-08 11:00 EST

X4 Pharmaceuticals Secures Up to $150 Million Senior Debt Facility with K2 HealthVentures

ALECAlector2026-10-07 20:05 EST

Alector to Host Virtual Research and Development Event Highlighting Wholly Owned Alector Brain Carrier (ABC)- Enabled Pipeline

STTKShattuck Labs2026-10-01 11:00 EST

Shattuck Labs Announces Phase 2 Clinical Trial of SL-325 in Hidradenitis Suppurativa and Appointment of Shoba Ravichandran, M.D., as Senior Vice President, Clinical Development

GRIGRI Bio2026-09-28 13:40 EST

GRI Bio to Highlight Immune Modulation and Phase 2a Development Insights in IPF at the 10th IPF Summit

NRIXNurix Therapeutics2026-11-03 21:01 EST

Nurix Therapeutics Announces Sanofi’s Decision to Discontinue Development of STAT6 Degrader SAR448272

ENTAEnanta Pharmaceuticals2026-10-13 11:00 EST

Enanta Pharmaceuticals to Present Data for Zelicapavir, an Oral, Once-Daily, N-Protein Inhibitor, in Development for the Treatment of Respiratory Syncytial Virus, at IDWeek™ 2026

HCMHUTCHMED2026-09-24 00:00 EST

HUTCHMED Highlights Clinical Data to be Presented at the ESMO Congress 2026

View all latest news

Inflarx NV

Complement-Targeted Immunology InflaRx develops anti-inflammatory therapies that inhibit the complement C5a pathway. Its portfolio includes an oral C5a receptor inhibitor and an antibody against C5a. Izicopan Izicopan is an oral C5aR inhibitor designed for differentiated chemistry, metabolic properties and safety. Phase 2a results in...

Recent company news

IFRXInflarx NV2026-11-03 12:00 EST

InflaRx Highlights Izicopan Development Path and Commercial Opportunity in ANCA-Associated Vasculitis at Capital Markets Day

IFRXInflarx NV2026-10-27 11:30 EST

InflaRx Announces November Investor Events

IFRXInflarx NV2026-10-22 16:00 EST

InflaRx Highlights Izicopan’s Therapeutic Potential at Kidney Week 2026

IFRXInflarx NV2026-10-02 11:30 EST

InflaRx to Present Late-Breaking Pre-clinical Data on Izicopan at Kidney Week 2026

IFRXInflarx NV2026-10-01 11:30 EST

InflaRx Appoints Gabriela Alperovich, MD, PhD, as Senior Vice President & Global Head of Clinical Development

Stock data

Close
1.36 USD
Market cap
319.63M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States